Q3 FY26 results: revenue up 23% YoY, PAT turns positive on lower one-time losses
HEALTHX · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts less than Nifty Microcap 250 and 0.3 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved Q3 and 9M FY26 unaudited results. Consolidated Q3 revenue from operations rose 22.9% YoY to Rs. 345.7 cr (9M: Rs. 945.5 cr vs Rs. 825.1 cr). 9M consolidated net profit was Rs. 11.5 cr versus a loss of Rs. 151.1 cr last year, helped by the absence of a Rs. 191 cr one-time loss on the Flipkart Health liquidation booked in the prior year. Healthcare segment drives growth. Standalone remains in loss with 9M loss of Rs. 80 lakh. Auditor flagged material going concern uncertainty at step-down subsidiary Genu Path Labs, whose net worth is fully eroded.
Topline growth is healthy but core profitability stays weak. Going concern flag at a subsidiary, standalone losses, and reliance on one-offs are key concerns. Watch healthcare margins.